Seres Therapeutics (MCRB) Financials

Seres Therapeutics logo
$1.44 +0.03 (+2.13%)
Closing price 04:00 PM Eastern
Extended Trading
$1.43 -0.01 (-0.62%)
As of 04:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Seres Therapeutics

Annual Income Statements for Seres Therapeutics

This table shows Seres Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-55 -92 -89 -99 -70 -89 -66 -250 -114 0.14 5.70
Consolidated Net Income / (Loss)
-55 -92 -89 -99 -70 -89 -66 -250 -114 0.14 5.70
Net Income / (Loss) Continuing Operations
-55 -92 -89 -99 -70 -89 -66 -184 -190 -126 5.70
Total Pre-Tax Income
-55 -92 -89 -99 -70 -89 -66 -184 -190 -126 5.70
Total Operating Income
-55 -93 -91 -100 -72 -88 -64 -180 -195 -121 -94
Total Gross Profit
0.00 22 32 28 35 33 145 0.00 0.00 0.00 0.79
Total Revenue
0.00 22 32 28 35 33 145 0.00 0.00 0.00 0.79
Operating Revenue
0.00 22 32 28 35 33 145 - 0.00 0.00 0.79
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
55 115 123 129 106 121 209 180 195 121 95
Selling, General & Admin Expense
17 33 34 33 25 31 69 70 78 53 39
Research & Development Expense
38 82 89 96 80 91 142 110 118 65 49
Other Operating Expenses / (Income)
- - - - 0.00 0.00 -1.73 0.00 0.00 3.53 6.54
Total Other Income / (Expense), net
0.08 1.26 2.02 1.34 1.60 -1.00 -1.09 -3.67 4.97 -4.46 100
Interest Expense
-0.08 - - 0.00 0.50 2.92 2.91 6.02 2.47 0.00 0.00
Interest & Investment Income
- 1.26 1.59 1.17 1.03 0.95 2.87 3.06 7.30 3.97 2.23
Other Income / (Expense), net
-0.01 - 0.43 0.17 1.07 0.98 -1.05 -0.71 0.13 -8.42 97
Net Income / (Loss) Discontinued Operations
- - - - - - - -67 76 126 0.00
Basic Earnings per Share
($2.33) ($2.30) ($2.21) ($2.43) ($1.24) ($1.12) ($0.72) ($2.31) ($17.77) $0.00 $0.64
Weighted Average Basic Shares Outstanding
23.53M 39.85M 40.45M 40.74M 56.65M 79.79M 91.70M 108.08M 6.40M 7.77M 8.86M
Diluted Earnings per Share
($2.33) ($2.30) ($2.21) ($2.43) ($1.24) ($1.12) ($0.72) ($2.31) ($17.77) $0.00 $0.64
Weighted Average Diluted Shares Outstanding
23.53M 39.85M 40.45M 40.74M 56.65M 79.79M 91.70M 108.08M 6.40M 7.77M 8.87M
Weighted Average Basic & Diluted Shares Outstanding
23.53M 39.85M 40.45M 40.74M 56.65M 79.79M 91.70M 126.08M 151.01M 174.36M 9.59M

Quarterly Income Statements for Seres Therapeutics

This table shows Seres Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-40 -33 89 -16 33 -20 8.20 -15 -20 4.58 -16
Consolidated Net Income / (Loss)
-40 -33 89 -16 33 -20 8.20 -15 -20 4.58 -16
Net Income / (Loss) Continuing Operations
-33 -26 -51 -1.73 0.00 -20 8.20 -15 0.00 4.58 -16
Total Pre-Tax Income
-33 -26 -51 -1.73 33 -20 8.20 -15 -20 4.58 -16
Total Operating Income
-34 -29 -29 -21 -27 -25 -22 -19 -21 -21 -16
Total Gross Profit
0.00 0.00 0.00 - 0.00 0.00 0.35 0.44 0.36 0.74 0.59
Total Revenue
0.00 0.00 0.00 - 0.00 0.00 0.35 0.44 0.36 0.74 0.59
Operating Revenue
- - 0.00 - 0.00 0.00 0.35 - 0.36 0.74 0.59
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
34 29 29 21 27 25 23 20 21 22 17
Selling, General & Admin Expense
15 13 13 8.95 12 10 9.48 7.54 8.07 7.06 5.45
Research & Development Expense
19 16 16 8.56 12 13 13 12 13 9.14 5.59
Other Operating Expenses / (Income)
0.00 0.00 0.00 - 3.53 1.69 0.74 0.59 0.00 0.00 0.00
Impairment Charge
- - - - - 0.00 0.00 - - 5.81 5.71
Total Other Income / (Expense), net
1.54 2.68 -22 19 60 5.03 31 4.04 0.99 26 -0.13
Interest & Investment Income
1.65 1.23 0.65 0.44 0.62 0.55 0.62 0.45 0.33 0.18 0.15
Other Income / (Expense), net
0.51 1.45 -23 11 59 4.48 30 3.60 0.67 26 -0.28
Other Gains / (Losses), net
- - - - - - - - - - -0.13
Basic Earnings per Share
($5.49) ($4.34) $11.63 ($0.09) $3.76 ($2.27) $0.94 ($1.73) ($2.08) $0.47 ($1.63)
Weighted Average Basic Shares Outstanding
7.31M 7.58M 7.63M 155.40M 8.70M 8.74M 8.76M 8.86M 9.58M 9.71M 9.98M
Diluted Earnings per Share
($5.49) ($4.34) $11.63 ($0.09) $3.75 ($2.27) $0.94 ($1.73) ($2.08) $0.47 ($1.63)
Weighted Average Diluted Shares Outstanding
7.31M 7.58M 7.63M 155.40M 8.71M 8.74M 8.77M 8.87M 9.58M 9.75M 9.98M
Weighted Average Basic & Diluted Shares Outstanding
151.45M 151.73M 170.74M 174.36M 8.73M 8.75M 9.05M 9.59M - 9.94M 10.20M

Annual Cash Flow Statements for Seres Therapeutics

This table details how cash moves in and out of Seres Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-40 -20 -20 50 -21 51 72 -17 -35 -97 15
Net Cash From Operating Activities
-41 44 -76 -63 -77 -94 6.69 -229 -117 -149 1.12
Net Cash From Continuing Operating Activities
-41 44 -76 -63 -77 -94 6.69 -229 -117 -149 1.12
Net Income / (Loss) Continuing Operations
-55 -92 -89 -99 -70 -89 -66 -250 -114 0.14 5.70
Consolidated Net Income / (Loss)
-55 -92 -89 -99 -70 -89 -66 -250 -114 0.14 5.70
Depreciation Expense
0.73 4.21 7.26 7.86 7.60 6.58 5.95 6.63 6.24 5.47 4.13
Amortization Expense
0.00 -0.39 0.22 -0.21 0.11 1.00 3.02 1.39 0.90 1.41 0.00
Non-Cash Adjustments To Reconcile Net Income
10 17 17 17 11 11 22 32 48 -92 21
Changes in Operating Assets and Liabilities, net
3.14 115 -11 12 -25 -23 42 -18 -59 -63 -29
Net Cash From Investing Activities
-137 -66 56 112 -31 -159 64 82 11 142 -0.04
Net Cash From Continuing Investing Activities
-137 -66 56 112 -31 -159 64 82 11 142 -0.04
Purchase of Property, Plant & Equipment
-4.36 -21 -4.68 -1.94 -1.00 -0.59 -9.57 -9.82 -7.98 -0.38 -0.25
Purchase of Investments
-268 -291 -98 -22 -46 -218 -96 -48 -4.43 0.00 0.00
Sale of Property, Plant & Equipment
- - - - - - - - 0.00 0.00 0.21
Divestitures
- - - - - - - 0.00 0.00 141 0.00
Sale and/or Maturity of Investments
136 246 158 136 17 60 170 140 23 1.40 0.00
Net Cash From Financing Activities
138 2.14 0.08 0.27 86 303 1.18 130 72 -90 14
Net Cash From Continuing Financing Activities
138 2.14 0.08 0.27 86 303 1.18 130 72 -90 14
Repayment of Debt
-2.60 - - 0.00 -0.43 0.00 -0.95 -1.91 -53 -128 0.00
Issuance of Debt
- - - 0.00 25 0.00 0.00 28 103 0.00 0.00
Issuance of Common Equity
143 - - 0.32 61 244 0.83 103 20 24 13
Other Financing Activities, net
0.26 2.14 0.08 -0.05 0.66 59 1.30 0.97 0.88 14 0.50
Cash Interest Paid
0.16 0.11 0.00 0.00 0.22 2.45 2.45 4.93 13 11 0.00

Quarterly Cash Flow Statements for Seres Therapeutics

This table details how cash moves in and out of Seres Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-17 -39 -4.41 -37 28 -13 2.26 -1.87 -16 -21 2.83
Net Cash From Operating Activities
-35 -40 -35 -39 27 -13 2.21 -15 -16 -22 -10
Net Cash From Continuing Operating Activities
-35 -40 -35 -39 27 -13 2.21 -15 -16 -22 -10
Net Income / (Loss) Continuing Operations
-40 -33 89 -16 33 -20 8.20 -15 -20 4.58 -16
Consolidated Net Income / (Loss)
-40 -33 89 -16 33 -20 8.20 -15 -20 4.58 -16
Depreciation Expense
1.56 1.42 1.40 1.09 1.08 1.06 1.04 0.95 0.78 0.67 0.48
Non-Cash Adjustments To Reconcile Net Income
12 7.79 -116 3.73 4.17 6.28 5.06 5.26 4.38 -15 8.75
Changes in Operating Assets and Liabilities, net
-9.15 -17 -9.59 -28 -11 -0.78 -12 -5.59 -1.61 -12 -3.42
Net Cash From Investing Activities
-0.06 1.30 141 -0.09 -0.03 -0.18 -0.01 0.18 0.00 0.01 13
Net Cash From Continuing Investing Activities
-0.06 1.30 141 -0.09 -0.03 -0.18 -0.01 0.18 0.00 0.01 13
Sale of Property, Plant & Equipment
- - - - - - - - - - 0.05
Net Cash From Financing Activities
19 - -111 1.74 1.18 - 0.06 13 0.43 1.72 0.75
Net Cash From Continuing Financing Activities
19 - -111 1.74 1.18 - 0.06 13 0.43 1.72 0.75
Issuance of Common Equity
19 - 3.52 1.74 1.18 - 0.05 12 0.43 1.72 0.75

Annual Balance Sheets for Seres Therapeutics

This table presents Seres Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
217 273 190 120 132 343 355 349 359 140 138
Total Current Assets
208 198 155 93 100 269 304 195 175 39 49
Cash & Equivalents
74 55 36 86 65 116 180 163 128 31 46
Accounts Receivable
- - - - 1.79 9.39 - - 0.00 0.00 0.16
Prepaid Expenses
2.53 5.13 5.10 6.85 3.59 5.77 13 13 8.05 5.81 3.09
Other Current Assets
- - - - - - - 0.00 - 2.07 0.36
Plant, Property, & Equipment, net
7.75 36 33 26 19 14 18 23 18 12 7.64
Total Noncurrent Assets
1.54 38 1.51 1.51 13 60 33 131 166 90 81
Other Noncurrent Operating Assets
- - 0.11 0.11 11 9.04 31 130 101 90 81
Total Liabilities & Shareholders' Equity
217 273 190 120 132 343 355 349 359 140 138
Total Liabilities
12 140 129 169 181 168 223 338 403 126 94
Total Current Liabilities
11 30 32 42 46 46 82 86 99 41 19
Accounts Payable
5.40 7.59 7.03 6.42 4.86 4.02 14 17 3.64 4.08 1.68
Accrued Expenses
5.52 11 13 15 11 14 45 60 23 28 7.25
Other Current Liabilities
- - - - 4.46 5.12 6.61 3.60 5.59 8.67 10
Total Noncurrent Liabilities
0.59 110 97 126 135 122 141 252 305 85 75
Other Noncurrent Operating Liabilities
- 0.00 1.13 0.64 16 12 29 109 94 85 75
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
205 133 61 -48 -48 175 132 11 -45 14 44
Total Preferred & Common Equity
205 133 61 -48 -48 175 132 11 -45 14 44
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
205 133 61 -48 -48 175 132 11 -45 14 44
Common Stock
288 307 324 341 411 724 746 875 933 992 1,017
Retained Earnings
-83 -174 -264 -389 -460 -549 -614 -865 -978 -978 -972

Quarterly Balance Sheets for Seres Therapeutics

This table presents Seres Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
368 341 322 179 164 144 143 118 102 66
Total Current Assets
214 165 149 73 66 49 52 32 42 34
Cash & Equivalents
170 111 71 67 59 45 48 30 16 18
Accounts Receivable
- - - - 2.76 0.88 0.35 0.23 0.27 0.18
Prepaid Expenses
9.10 4.61 6.44 6.10 4.47 2.42 3.11 1.77 1.48 4.21
Other Current Assets
17 7.42 19 - - - 0.43 0.00 25 13
Plant, Property, & Equipment, net
24 19 18 13 11 9.62 8.58 6.85 5.80 3.00
Total Noncurrent Assets
130 157 155 93 88 85 83 79 53 28
Other Noncurrent Operating Assets
128 156 155 93 88 85 83 79 53 28
Total Liabilities & Shareholders' Equity
368 341 322 179 164 144 143 118 102 66
Total Liabilities
383 401 409 155 114 111 100 91 67 45
Total Current Liabilities
79 98 108 65 31 31 22 19 20 21
Accounts Payable
8.96 5.22 4.81 8.25 2.17 2.20 1.68 2.34 1.19 1.46
Accrued Expenses
54 76 86 18 6.22 5.81 11 6.14 7.02 6.78
Other Current Liabilities
6.28 17 17 39 23 23 9.92 11 12 13
Total Noncurrent Liabilities
304 303 301 90 82 80 77 72 47 24
Other Noncurrent Operating Liabilities
107 105 103 90 82 80 77 72 47 24
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-15 -60 -87 24 50 33 44 26 35 21
Total Preferred & Common Equity
-15 -60 -87 24 50 33 44 26 35 21
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
-15 -60 -87 24 50 33 44 26 35 21
Common Stock
922 959 964 986 996 998 1,001 1,019 1,022 1,025
Retained Earnings
-937 -1,018 -1,051 -962 -945 -965 -957 -992 -988 -1,004

Annual Metrics And Ratios for Seres Therapeutics

This table displays calculated financial ratios and metrics derived from Seres Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
39,055,767.00 40,355,753.00 40,530,139.00 40,855,909.00 69,993,952.00 91,248,238.00 91,847,137.00 124,591,741.00 129,257,199.00 - 9,046,519.00
DEI Adjusted Shares Outstanding
1,952,788.00 2,017,788.00 2,026,507.00 2,042,795.00 3,499,698.00 4,562,412.00 4,592,357.00 6,229,587.00 6,462,860.00 - 9,046,519.00
DEI Earnings Per Adjusted Shares Outstanding
-28.05 -45.39 -44.11 -48.43 -20.08 -19.55 -14.28 -40.16 -17.60 - 0.63
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 47.48% -11.94% 22.07% -3.74% 336.33% -100.00% 0.00% 0.00% 0.00%
EBITDA Growth
-231.91% -64.44% 6.21% -10.74% 31.76% -26.11% 28.91% -205.12% -8.82% 34.59% 106.19%
EBIT Growth
-232.50% -69.22% 2.01% -10.05% 29.27% -23.07% 24.80% -175.59% -7.94% 33.46% 102.67%
NOPAT Growth
-263.72% -69.24% 1.56% -9.73% 28.33% -22.61% 26.82% -178.97% -8.44% 37.82% -10.66%
Net Income Growth
-227.85% -67.18% 2.40% -10.70% 28.97% -26.82% 26.42% -281.46% 54.54% 100.12% 4,088.24%
EPS Growth
12.73% 1.29% 3.91% -9.95% 48.97% 9.68% 35.71% -220.83% 54.54% 100.00% 0.00%
Operating Cash Flow Growth
-294.32% 207.53% -271.95% 16.78% -21.74% -22.33% 107.14% -3,521.29% 48.71% -26.63% 100.75%
Free Cash Flow Firm Growth
-398.08% 155.68% -413.83% 66.71% -151.70% -30.00% 82.12% -933.37% -82.62% 74.06% -63.28%
Invested Capital Growth
74.14% -13,633.85% 7.20% -57.28% 6.69% 12.42% -29.96% 11.39% 100.74% -2,013.27% 90.90%
Revenue Q/Q Growth
0.00% 16.22% 0.06% 36.60% -8.02% 42.72% -6.66% -100.00% -100.00% -100.00% 124.79%
EBITDA Q/Q Growth
0.00% -10.67% -3.73% 7.93% 5.35% 3.50% -131.59% 21.64% -47.58% 20.03% 11.45%
EBIT Q/Q Growth
0.00% -11.90% -4.19% 7.63% 4.77% 2.54% -93.35% 20.99% -45.32% 19.65% 35.67%
NOPAT Q/Q Growth
0.00% -12.17% -4.68% 7.48% 3.33% 1.45% -95.68% 20.96% -45.66% 14.84% 9.15%
Net Income Q/Q Growth
0.00% -12.57% -4.29% 7.19% 3.45% 0.59% -93.85% -8.12% 19.50% 100.53% 5.60%
EPS Q/Q Growth
0.00% -223.94% -3.76% 7.60% 21.52% -1.82% -7,100.00% 14.76% 19.50% 100.00% 3.23%
Operating Cash Flow Q/Q Growth
-22.32% -17.37% 0.26% 34.61% -53.63% -4.32% -83.54% -0.45% 4.39% 5.48% 104.84%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 7.97% 59.63% -93.71% -7.38% -161.20% 28.36% -107.66% 52.84% 23.15%
Invested Capital Q/Q Growth
0.00% 5.50% -4.90% -34.16% -2.12% 3.39% 11.47% -4.27% 101.04% 60.36% 60.72%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00% 100.00%
EBITDA Margin
0.00% -408.99% -260.11% -327.12% -182.87% -239.57% -39.03% 0.00% 0.00% 0.00% 963.50%
Operating Margin
0.00% -426.53% -284.72% -354.77% -208.31% -265.33% -44.50% 0.00% 0.00% 0.00% -11,910.14%
EBIT Margin
0.00% -426.53% -283.40% -354.17% -205.22% -262.38% -45.22% 0.00% 0.00% 0.00% 439.67%
Profit (Net Income) Margin
0.00% -420.74% -278.44% -350.03% -203.68% -268.33% -45.25% 0.00% 0.00% 0.00% 721.93%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 136.27% 59.81% -0.11% 100.00%
Interest Burden Percent
99.85% 98.64% 98.25% 98.83% 99.25% 102.27% 100.06% 101.64% 97.52% 96.94% 164.20%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-34.81% -54.18% -92.46% -1,563.81% 145.85% -140.99% -42.83% -351.62% 667.53% -0.88% 19.64%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -29,062.87% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% -37.93% -39.37% -64.59% -56.00% -36.67% -18.78% 0.00% 0.00% 0.00% 2.50%
Return on Assets (ROA)
0.00% -37.41% -38.68% -63.83% -55.58% -37.50% -18.80% 0.00% 0.00% 0.00% 4.10%
Return on Common Equity (ROCE)
-19.76% -54.18% -92.46% -1,563.81% 145.85% -140.99% -42.83% -351.62% 667.53% -0.88% 19.64%
Return on Equity Simple (ROE_SIMPLE)
-26.67% -69.05% -147.25% 205.94% 145.43% -51.00% -49.87% -2,319.92% 0.00% 0.99% 0.00%
Net Operating Profit after Tax (NOPAT)
-38 -65 -64 -70 -50 -62 -45 -126 -137 -85 -94
NOPAT Margin
0.00% -298.57% -199.30% -248.34% -145.81% -185.73% -31.15% 0.00% 0.00% 0.00% -11,910.14%
Net Nonoperating Expense Percent (NNEP)
-10.31% -12.46% -13.99% -25.80% -26.27% -15.62% -7.46% -62.16% 53.16% -1,137.73% 260.37%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - -203.69% -240.91% -616.08% -212.52%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 149.85% 106.04% 115.31% 71.72% 92.65% 47.79% 0.00% 0.00% 0.00% 4,962.74%
R&D to Revenue
0.00% 376.68% 278.68% 339.46% 232.26% 272.68% 97.91% 0.00% 0.00% 0.00% 6,218.00%
Operating Expenses to Revenue
0.00% 526.53% 384.72% 454.77% 308.31% 365.33% 144.50% 0.00% 0.00% 0.00% 12,010.14%
Earnings before Interest and Taxes (EBIT)
-55 -93 -91 -100 -71 -87 -66 -181 -195 -130 3.47
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-54 -89 -83 -92 -63 -80 -57 -173 -188 -123 7.60
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
6.67 3.01 6.77 0.00 0.00 12.79 5.82 64.71 0.00 10.29 3.04
Price to Tangible Book Value (P/TBV)
6.67 3.01 6.77 0.00 0.00 12.79 5.82 64.71 0.00 10.29 3.04
Price to Revenue (P/Rev)
0.00 18.36 12.80 6.53 7.00 67.31 5.28 0.00 0.00 0.00 170.61
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1,043.26 23.63
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.10% 4.23%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 172.26 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 8.28 8.37 3.69 4.92 58.88 3.43 0.00 0.00 0.00 112.61
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 11.69
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 25.61
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 4.10 0.00 0.00 0.00 0.00 74.33 0.00 0.00 0.00 79.54
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 8.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.08 0.15 -0.14 -0.51 0.14 0.19 4.73 -2.26 0.00 0.00
Long-Term Debt to Equity
0.00 0.08 0.15 -0.14 -0.51 0.14 0.19 4.69 -2.26 0.00 0.00
Financial Leverage
-1.01 -1.26 -1.88 -17.61 1.58 -2.78 -1.79 -2.81 2.52 -0.48 -1.32
Leverage Ratio
1.06 1.45 2.39 24.50 -2.62 3.76 2.28 4.95 -20.76 -16.04 4.79
Compound Leverage Factor
1.06 1.43 2.35 24.21 -2.60 3.85 2.28 5.03 -20.25 -15.55 7.87
Debt to Total Capital
0.28% 7.48% 12.90% -16.42% -104.11% 12.56% 15.78% 82.56% 179.13% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.23% 0.00% 0.74% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.28% 7.48% 12.90% -16.42% -104.11% 12.33% 15.78% 81.82% 179.13% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
99.72% 92.52% 87.10% 116.42% 204.11% 87.44% 84.22% 17.44% -79.13% 100.00% 100.00%
Debt to EBITDA
-0.01 -0.12 -0.11 -0.07 -0.39 -0.32 -0.44 -0.30 -0.54 0.00 0.00
Net Debt to EBITDA
3.78 2.46 1.71 0.87 1.13 3.52 4.74 0.76 0.15 0.00 0.00
Long-Term Debt to EBITDA
-0.01 -0.12 -0.11 -0.07 -0.39 -0.31 -0.44 -0.29 -0.54 0.00 0.00
Debt to NOPAT
-0.02 -0.17 -0.14 -0.10 -0.49 -0.41 -0.55 -0.41 -0.74 0.00 0.00
Net Debt to NOPAT
5.33 3.37 2.23 1.15 1.42 4.53 5.94 1.05 0.20 0.00 0.00
Long-Term Debt to NOPAT
-0.02 -0.17 -0.14 -0.10 -0.49 -0.40 -0.55 -0.40 -0.74 0.00 0.00
Altman Z-Score
71.19 0.51 -0.67 -5.87 -5.07 5.77 0.18 -3.56 -5.09 -12.20 -8.64
Noncontrolling Interest Sharing Ratio
43.23% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
19.01 6.51 4.90 2.20 2.18 5.79 3.69 2.28 1.78 0.94 2.56
Quick Ratio
18.78 6.34 4.74 2.04 2.10 5.67 3.53 2.12 1.30 0.80 2.38
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-40 22 -70 -23 -59 -77 -14 -141 -258 -67 -109
Operating Cash Flow to CapEx
-936.36% 204.36% -1,615.12% -3,244.91% -7,636.73% -15,839.26% 69.91% -2,329.86% -1,471.52% -39,107.63% 2,659.52%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 -117.35 -26.19 -4.70 -23.50 -104.69 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 -152.43 -32.01 2.30 -38.01 -47.55 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 -154.43 -32.22 -0.99 -39.64 -50.78 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.09 0.14 0.18 0.27 0.14 0.42 0.00 0.00 0.00 0.01
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 5.95 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.99 0.93 0.95 1.51 1.99 9.10 0.00 0.00 0.00 0.08
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 61.38 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 61.38 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-0.64 -88 -82 -128 -120 -105 -136 -121 0.89 -17 -1.55
Invested Capital Turnover
0.00 -0.49 -0.38 -0.27 -0.28 -0.30 -1.20 0.00 0.00 0.00 -0.09
Increase / (Decrease) in Invested Capital
1.84 -87 6.34 -47 8.60 15 -31 16 122 -18 15
Enterprise Value (EV)
1,166 180 269 104 170 1,956 497 566 153 111 89
Market Capitalization
1,370 400 411 185 241 2,236 765 698 181 142 135
Book Value per Share
$5.26 $3.29 $1.50 ($1.18) ($0.69) $1.92 $1.43 $0.09 ($0.35) $0.08 $4.89
Tangible Book Value per Share
$5.26 $3.29 $1.50 ($1.18) ($0.69) $1.92 $1.43 $0.09 ($0.35) $0.08 $4.89
Total Capital
206 143 70 -41 -24 200 156 62 57 14 44
Total Debt
0.59 11 8.99 6.78 25 25 25 51 102 0.00 0.00
Total Long-Term Debt
0.59 11 8.99 6.78 25 25 25 51 102 0.00 0.00
Net Debt
-204 -219 -142 -80 -72 -280 -268 -132 -28 -31 -46
Capital Expenditures (CapEx)
4.36 21 4.68 1.94 1.00 0.59 9.57 9.82 7.98 0.38 0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-8.39 -25 -27 -35 -41 -31 -69 -72 -51 -33 -16
Debt-free Net Working Capital (DFNWC)
197 168 123 51 54 223 221 110 77 -2.55 30
Net Working Capital (NWC)
197 168 123 51 54 222 221 109 77 -2.55 30
Net Nonoperating Expense (NNE)
16 27 25 29 20 27 20 124 -23 -85 -100
Net Nonoperating Obligations (NNO)
-206 -221 -142 -80 -72 -280 -268 -132 46 -31 -46
Total Depreciation and Amortization (D&A)
0.73 3.82 7.48 7.65 7.71 7.58 8.97 8.02 7.15 6.88 4.13
Debt-free, Cash-free Net Working Capital to Revenue
0.00% -116.38% -82.65% -124.51% -117.72% -92.73% -47.84% 0.00% 0.00% 0.00% -1,991.38%
Debt-free Net Working Capital to Revenue
0.00% 771.44% 384.59% 179.09% 157.07% 670.83% 152.75% 0.00% 0.00% 0.00% 3,809.13%
Net Working Capital to Revenue
0.00% 771.44% 384.59% 179.09% 157.07% 669.46% 152.75% 0.00% 0.00% 0.00% 3,809.13%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($2.33) ($2.30) ($2.21) ($2.43) ($1.24) ($1.12) ($0.72) ($2.31) ($17.80) $0.00 $0.64
Adjusted Weighted Average Basic Shares Outstanding
39.19M 40.37M 40.65M 41.05M 71.07M 91.55M 92.01M 108.08M 6.40M 155.40M 8.86M
Adjusted Diluted Earnings per Share
($2.33) ($2.30) ($2.21) ($2.43) ($1.24) ($1.12) ($0.72) ($2.31) ($17.80) $0.00 $0.64
Adjusted Weighted Average Diluted Shares Outstanding
39.19M 40.37M 40.65M 41.05M 71.07M 91.55M 92.01M 108.08M 6.40M 155.40M 8.87M
Adjusted Basic & Diluted Earnings per Share
($2.33) ($2.30) ($2.21) ($2.43) ($1.24) ($1.12) ($0.72) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
23.53M 39.85M 40.45M 40.74M 56.65M 79.79M 91.70M 126.08M 7.55M 174.36M 9.59M
Normalized Net Operating Profit after Tax (NOPAT)
-38 -65 -64 -70 -49 -62 -45 -126 -137 -85 -66
Normalized NOPAT Margin
0.00% -298.57% -199.30% -248.34% -142.79% -185.73% -31.15% 0.00% 0.00% 0.00% -8,337.10%
Pre Tax Income Margin
0.00% -420.74% -278.44% -350.03% -203.68% -268.33% -45.25% 0.00% 0.00% 0.00% 721.93%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 -141.06 -29.80 -22.52 -30.00 -79.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 -100.23 -21.10 -15.51 -20.92 -55.34 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 -143.05 -30.01 -25.81 -31.63 -82.23 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 -102.22 -21.30 -18.80 -22.55 -58.57 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Seres Therapeutics

This table displays calculated financial ratios and metrics derived from Seres Therapeutics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
151,009,462.00 151,447,763.00 151,730,995.00 - 174,358,753.00 8,732,422.00 8,754,570.00 9,046,519.00 9,586,298.00 9,586,298.00 9,941,261.00
DEI Adjusted Shares Outstanding
7,550,473.00 7,572,388.00 7,586,550.00 - 8,717,938.00 8,732,422.00 8,754,570.00 9,046,519.00 9,586,298.00 9,586,298.00 9,941,261.00
DEI Earnings Per Adjusted Shares Outstanding
-5.32 -4.34 11.70 - 3.75 -2.27 0.94 -1.70 -2.08 0.48 -1.64
Growth Metrics
- - - - - - - - - - -
Revenue Growth
100.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 68.95%
EBITDA Growth
53.66% -151.41% -20.02% 92.77% 203.86% 24.21% 117.32% 5.00% -158.71% 126.21% -284.83%
EBIT Growth
51.70% -157.12% -18.58% 92.04% 194.49% 25.61% 114.68% 5.46% -163.12% 121.57% -316.61%
NOPAT Growth
51.20% -140.81% 34.58% 83.61% -12.98% 13.82% -10.08% 32.80% 46.27% -22.14% 49.70%
Net Income Growth
43.61% -170.61% 285.51% 62.09% 181.43% 39.60% -90.76% 1.93% -160.93% 123.07% -298.51%
EPS Growth
43.61% -170.61% 285.51% 70.97% 181.43% 47.70% -91.92% 13.93% -155.47% 120.70% -273.40%
Operating Cash Flow Growth
53.99% -160.33% 41.47% 18.14% 176.37% 66.62% 106.36% 62.17% -160.80% -68.52% -574.93%
Free Cash Flow Firm Growth
7.08% -314.28% -1.53% 101.43% -52.75% 15.51% 2.19% -1,169.01% 77.92% 13.42% 68.95%
Invested Capital Growth
32.77% 48.11% 49.70% -2,013.27% 88.08% 77.73% 90.81% 90.90% 60.22% 252.39% 197.21%
Revenue Q/Q Growth
100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 24.79% -18.26% 105.59% -19.43%
EBITDA Q/Q Growth
74.89% 20.02% -95.21% 81.54% 312.34% -158.36% 144.62% -271.80% -31.24% 126.06% -414.62%
EBIT Q/Q Growth
73.72% 19.18% -88.46% 80.11% 292.09% -163.63% 137.18% -308.01% -28.25% 121.74% -473.45%
NOPAT Q/Q Growth
73.40% 16.17% -1.04% 27.27% -34.93% 36.05% -29.05% 39.65% -7.90% -45.36% 46.85%
Net Income Q/Q Growth
2.70% 18.10% 370.08% -117.61% 309.00% -160.75% 141.32% -286.92% -29.85% 123.01% -455.51%
EPS Q/Q Growth
2.70% 18.10% 370.08% -115.52% 309.00% -160.53% 141.41% -284.04% -20.23% 122.60% -446.81%
Operating Cash Flow Q/Q Growth
25.82% -12.98% 12.89% -12.12% 169.21% -149.38% 116.60% -766.82% -11.22% -36.88% 53.22%
Free Cash Flow Firm Q/Q Growth
72.52% -23.28% 12.71% 104.85% -3,798.48% 31.81% -1.05% 52.76% 32.18% -167.44% 63.76%
Invested Capital Q/Q Growth
-8,009.34% 20.62% 23.13% 60.36% 50.71% -48.25% 68.29% 60.72% -115.44% 667.92% -79.77%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,458.69% -3,384.93% -5,434.92% 688.86% -2,689.88%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -6,403.70% -4,423.97% -5,839.94% -2,890.35% -2,723.78%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,161.25% -3,602.74% -5,653.07% 597.83% -2,770.99%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,337.32% -3,501.14% -5,562.29% 622.42% -2,746.37%
Tax Burden Percent
121.97% 125.48% -173.95% 902.31% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
96.96% 95.52% 98.74% 16.86% 101.93% 97.32% 108.15% 97.18% 98.39% 104.11% 99.11%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,671.80% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,756.60% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,587.12% 0.00%
Return on Equity (ROE)
153.67% 502.96% -579.24% -0.88% -1,573.41% -317.66% 15.95% 19.64% -121.87% -84.68% -144.35%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -476.20% -1,622.77%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.71% -20.45% -46.02% 9.17% -56.25%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 5.09% -19.87% -45.28% 9.55% -55.75%
Return on Common Equity (ROCE)
153.67% 502.96% -579.24% -0.88% -1,573.41% -317.66% 15.95% 19.64% -121.87% -84.68% -144.35%
Return on Equity Simple (ROE_SIMPLE)
138.41% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-24 -20 -20 -15 -27 -17 -22 -14 -15 -21 -11
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -6,403.70% -3,096.78% -4,087.96% -2,890.35% -1,906.64%
Net Nonoperating Expense Percent (NNEP)
-47.64% -25.60% 159.41% 10.53% 172.61% -34.54% 53.61% -4.63% -11.90% 84.80% -15.28%
Return On Investment Capital (ROIC_SIMPLE)
-57.03% -131.06% -85.37% -107.73% -53.97% -52.86% -51.44% -30.68% -55.23% -61.60% -52.94%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,699.72% 1,721.23% 2,254.19% 959.38% 918.72%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3,594.30% 2,667.58% 3,685.75% 1,241.98% 943.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6,503.70% 4,523.97% 5,939.94% 2,990.35% 2,823.78%
Earnings before Interest and Taxes (EBIT)
-34 -27 -52 -10 32 -20 7.59 -16 -20 4.40 -16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-32 -26 -50 -9.20 33 -19 8.63 -15 -19 5.07 -16
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 6.00 10.29 2.42 2.94 3.85 3.04 3.21 2.19 1.56
Price to Tangible Book Value (P/TBV)
0.00 0.00 6.00 10.29 2.42 2.94 3.85 3.04 3.21 2.19 1.56
Price to Revenue (P/Rev)
223.94 0.00 0.00 0.00 0.00 0.00 479.88 170.61 74.13 40.17 15.67
Price to Earnings (P/E)
0.00 0.00 0.00 1,043.26 1.67 1.13 31.23 23.63 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.10% 59.76% 88.61% 3.20% 4.23% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.17 4.12
Enterprise Value to Revenue (EV/Rev)
203.68 0.00 0.00 0.00 0.00 0.00 344.16 112.61 48.12 31.89 7.42
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 17.71 11.69 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 47.24 25.61 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 79.54 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
-1.71 -1.18 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
-1.71 -1.18 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
0.63 1.53 -15.58 -0.48 7.49 0.26 -1.69 -1.32 -1.15 -0.90 -1.00
Leverage Ratio
-5.68 -11.30 62.12 -16.04 -54.51 -8.60 4.77 4.79 3.66 3.64 3.22
Compound Leverage Factor
-5.51 -10.79 61.34 -2.70 -55.56 -8.37 5.15 4.66 3.60 3.79 3.19
Debt to Total Capital
241.32% 664.68% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
241.32% 664.68% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
-141.32% -564.68% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
-0.68 -0.45 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.07 -0.14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
-0.68 -0.45 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
-0.92 -0.62 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.10 -0.19 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
-0.92 -0.62 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-4.09 -4.93 -8.59 -9.38 -6.52 -9.19 -7.91 -9.10 -11.68 -12.51 -21.43
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.68 1.38 1.12 0.94 2.11 1.57 2.30 2.56 1.65 2.11 1.65
Quick Ratio
1.13 0.66 1.03 0.80 1.97 1.50 2.14 2.38 1.55 0.79 0.85
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-58 -72 -63 3.05 -89 -61 -61 -29 -20 -53 -19
Operating Cash Flow to CapEx
-56,832.26% -40,213.13% -26,883.72% -43,202.22% 79,147.06% -7,341.99% 27,575.00% -50,724.14% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
-94.46 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
-57.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
-57.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.02 0.02
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.77 3.26 7.96
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.02 0.00 0.00 0.00 0.00 0.00 0.03 0.08 0.13 0.24 0.37
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 476.38 112.04 45.86
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 476.38 112.04 45.86
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-70 -56 -43 -17 -8.38 -12 -3.94 -1.55 -3.34 19 3.83
Invested Capital Turnover
-0.01 0.00 0.00 0.00 0.00 0.00 -0.02 -0.09 -0.20 0.58 -38.64
Increase / (Decrease) in Invested Capital
34 52 42 -18 62 43 39 15 5.05 31 7.77
Enterprise Value (EV)
106 141 77 111 63 52 121 89 55 60 16
Market Capitalization
117 110 144 142 122 97 168 135 85 76 33
Book Value per Share
($0.40) ($0.57) $0.16 $0.08 $0.29 $3.77 $4.99 $4.89 $2.76 $3.56 $2.15
Tangible Book Value per Share
($0.40) ($0.57) $0.16 $0.08 $0.29 $3.77 $4.99 $4.89 $2.76 $3.56 $2.15
Total Capital
42 15 24 14 50 33 44 44 26 35 21
Total Debt
102 102 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
102 102 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-11 31 -67 -31 -59 -45 -48 -46 -30 -16 -18
Capital Expenditures (CapEx)
0.06 0.10 0.13 0.09 0.03 0.18 0.01 0.03 0.00 0.00 -0.05
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-44 -30 -59 -33 -24 -28 -19 -16 -17 6.72 -4.00
Debt-free Net Working Capital (DFNWC)
67 41 8.10 -2.55 35 18 29 30 12 22 14
Net Working Capital (NWC)
67 41 8.10 -2.55 35 18 29 30 12 22 14
Net Nonoperating Expense (NNE)
16 13 -109 0.79 -60 2.44 -31 1.77 5.28 -26 4.98
Net Nonoperating Obligations (NNO)
-11 31 -67 -31 -59 -45 -48 -46 -30 -16 -18
Total Depreciation and Amortization (D&A)
2.02 1.91 1.87 1.09 1.08 1.06 1.04 0.95 0.78 0.67 0.48
Debt-free, Cash-free Net Working Capital to Revenue
-8,521.26% 0.00% 0.00% 0.00% 0.00% 0.00% -5,282.05% -1,991.38% -1,511.86% 357.04% -188.14%
Debt-free Net Working Capital to Revenue
12,778.35% 0.00% 0.00% 0.00% 0.00% 0.00% 8,290.03% 3,809.13% 1,089.19% 1,185.18% 636.71%
Net Working Capital to Revenue
12,778.35% 0.00% 0.00% 0.00% 0.00% 0.00% 8,290.03% 3,809.13% 1,089.19% 1,185.18% 636.71%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($5.40) ($4.40) $11.60 ($0.09) $3.76 ($2.27) $0.94 ($1.73) ($2.08) $0.47 ($1.63)
Adjusted Weighted Average Basic Shares Outstanding
7.31M 7.58M 7.63M 155.40M 8.70M 8.74M 8.76M 8.86M 9.58M 9.71M 9.98M
Adjusted Diluted Earnings per Share
($5.40) ($4.40) $11.60 ($0.09) $3.75 ($2.27) $0.94 ($1.73) ($2.08) $0.47 ($1.63)
Adjusted Weighted Average Diluted Shares Outstanding
7.31M 7.58M 7.63M 155.40M 8.71M 8.74M 8.77M 8.87M 9.58M 9.75M 9.98M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($1.73) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
7.57M 7.59M 8.54M 174.36M 8.73M 8.75M 9.05M 9.59M 0.00 9.94M 10.20M
Normalized Net Operating Profit after Tax (NOPAT)
-24 -20 -20 -15 -19 -17 -16 -14 -15 -11 -7.31
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4,482.59% -3,096.78% -4,087.96% -1,470.95% -1,233.20%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,337.32% -3,501.14% -5,562.29% 622.42% -2,746.37%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-54.91 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
-39.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
-55.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
-39.11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Seres Therapeutics’ financial position has improved in some areas, but the company remains heavily dependent on external financing and non-operating income. Revenue has returned, liabilities have declined substantially, and shareholders’ equity is positive again. However, operating losses and cash burn remain significant, while the latest quarterly profit was driven primarily by a large non-operating gain rather than the company’s core business.

  • Revenue is trending upward. Quarterly revenue increased from $351,000 in Q3 2025 to $438,000 in Q4, $358,000 in Q1 2026 and $736,000 in Q2 2026. Although the base remains small, the latest quarter represented more than a 100% sequential increase from Q1.
  • Operating expenses have generally declined from 2024 levels. Selling, general and administrative expense fell to $7.1 million in Q2 2026 from $14.9 million in Q1 2024, while research and development expense declined to $9.1 million from $19.5 million over the same comparison. Lower spending could help extend Seres’ remaining resources if maintained.
  • Total liabilities have fallen sharply. Liabilities declined from $408.8 million in Q2 2024 to $67.1 million in Q2 2026. Noncurrent liabilities decreased to $47.0 million from more than $300 million during 2024, materially improving the company’s balance-sheet structure.
  • Shareholders’ equity has returned to positive territory. Seres reported negative equity of $87.1 million in Q2 2024 and negative $15.1 million in Q3 2023, but equity reached $34.5 million by Q2 2026. This improvement reflects liability reductions and changes in the company’s capital structure.
  • Liquidity remains supported by current assets. Q2 2026 total current assets were $42.3 million versus $20.0 million of current liabilities, producing a current ratio of approximately 2.1. The balance sheet also included $25.0 million of other current assets, although investors should review the composition and liquidity of that balance.
  • Q2 2026 reported a $4.6 million profit, but the result was not driven by operations. Operating loss was $21.3 million, while other income totaled $25.9 million, including $25.7 million of other income. This produced positive earnings per share of $0.47, but the gain may not be repeatable.
  • Recent financial statements include restatements and unusual items. Several 2024 and 2025 income statements are identified as restated, and reported results include discontinued operations, impairment charges and substantial other income. These items make year-over-year comparisons less representative of ongoing operating performance.
  • Cash is being depleted rapidly. Cash and equivalents declined from $169.9 million in Q3 2023 to $15.6 million in Q2 2026. The balance fell from $29.8 million at the end of Q1 2026, a decrease of approximately 48% in one quarter.
  • Operating cash flow remains deeply negative. Seres used $22.4 million in operating cash during Q2 2026, following outflows of $16.4 million in Q1 and $14.7 million in Q4 2025. The company’s latest quarterly operating cash burn exceeded its $15.6 million cash balance at quarter-end.
  • Core operations remain unprofitable and additional financing may be necessary. Q2 2026 operating expenses totaled $22.0 million against only $736,000 of revenue, resulting in a $21.3 million operating loss. Seres also issued $1.7 million of common equity during the quarter, continuing a pattern of equity financing that can dilute existing shareholders.

Overall, Seres Therapeutics shows progress in revenue generation, cost reduction, liability management and equity restoration. Nevertheless, the company’s core business has not yet reached profitability, and its cash balance is declining faster than operating improvements are offsetting losses. Investors should focus on whether revenue growth becomes durable, whether operating cash burn decreases materially and whether future funding can be secured without substantial shareholder dilution.

11/18/26 06:57 PM ETAI Generated. May Contain Errors.

Seres Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Seres Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Seres Therapeutics' net income appears to be on an upward trend, with a most recent value of $5.70 million in 2025, compared with -$54.78 million in 2015. The previous period was $136 thousand in 2024. See Seres Therapeutics' forecast for analyst expectations on what's next for the company.

Seres Therapeutics' total operating income in 2025 was -$93.97 million, based on the following breakdown:
  • Total Gross Profit: $789 thousand
  • Total Operating Expenses: $94.76 million

Over the last 10 years, Seres Therapeutics' total revenue changed from $0.00 in 2015 to $789 thousand in 2025, a change of 78,900,000.0%.

In the past 12 quarters, Seres Therapeutics' cash and equivalents has ranged from $15.59 million in Q2 2026 to $169.91 million in Q3 2023, and is currently $17.53 million as of their latest financial filing in Q3 2026.

Seres Therapeutics had total debt of $0.00 at the end of 2025, compared with none in 2024, and a 100.0% decrease since 2015.

Over the last 10 years, Seres Therapeutics' book value per share changed from 5.26 in 2015 to 4.89 in 2025, a change of -7.1%.



Financial statements for NASDAQ:MCRB last updated on 11/4/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners